Varma Mutual Pension Insurance Co Has $26.72 Million Position in Boston Scientific Corporation $BSX

Varma Mutual Pension Insurance Co increased its stake in shares of Boston Scientific Corporation (NYSE:BSX) by 3.4% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 280,181 shares of the medical equipment provider’s stock after buying an additional 9,300 shares during the quarter. Varma Mutual Pension Insurance Co’s holdings in Boston Scientific were worth $26,715,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in BSX. Financial Consulate Inc. acquired a new stake in Boston Scientific during the third quarter worth approximately $25,000. Murphy & Mullick Capital Management Corp boosted its holdings in shares of Boston Scientific by 200.0% in the 3rd quarter. Murphy & Mullick Capital Management Corp now owns 255 shares of the medical equipment provider’s stock valued at $25,000 after purchasing an additional 170 shares in the last quarter. FWL Investment Management LLC acquired a new stake in shares of Boston Scientific in the 2nd quarter valued at $26,000. United Community Bank boosted its holdings in shares of Boston Scientific by 115.7% in the 3rd quarter. United Community Bank now owns 274 shares of the medical equipment provider’s stock valued at $27,000 after purchasing an additional 147 shares in the last quarter. Finally, Colonial Trust Co SC boosted its holdings in shares of Boston Scientific by 502.2% in the 3rd quarter. Colonial Trust Co SC now owns 277 shares of the medical equipment provider’s stock valued at $27,000 after purchasing an additional 231 shares in the last quarter. Institutional investors and hedge funds own 89.07% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on the company. Oppenheimer set a $90.00 target price on Boston Scientific in a report on Thursday, April 23rd. Truist Financial reduced their target price on Boston Scientific from $90.00 to $85.00 and set a “buy” rating on the stock in a report on Thursday, April 23rd. Stifel Nicolaus reduced their target price on Boston Scientific from $90.00 to $85.00 and set a “buy” rating on the stock in a report on Tuesday, April 21st. TD Cowen reduced their target price on Boston Scientific from $115.00 to $100.00 and set a “buy” rating on the stock in a report on Monday, February 2nd. Finally, Barclays reduced their target price on Boston Scientific from $124.00 to $96.00 and set an “overweight” rating on the stock in a report on Thursday, April 23rd. One research analyst has rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, Boston Scientific currently has an average rating of “Moderate Buy” and an average target price of $93.91.

Boston Scientific Trading Up 0.3%

Shares of NYSE BSX opened at $56.64 on Monday. The firm has a 50 day moving average price of $67.06 and a two-hundred day moving average price of $84.57. The stock has a market cap of $84.18 billion, a P/E ratio of 23.70, a price-to-earnings-growth ratio of 1.04 and a beta of 0.62. Boston Scientific Corporation has a 52-week low of $56.05 and a 52-week high of $109.50. The company has a debt-to-equity ratio of 0.46, a quick ratio of 1.08 and a current ratio of 1.62.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings results on Wednesday, April 22nd. The medical equipment provider reported $0.80 EPS for the quarter, topping analysts’ consensus estimates of $0.79 by $0.01. Boston Scientific had a net margin of 17.29% and a return on equity of 19.68%. The company had revenue of $5.20 billion for the quarter, compared to analyst estimates of $5.19 billion. During the same quarter in the previous year, the business earned $0.75 earnings per share. Boston Scientific’s revenue was up 11.6% compared to the same quarter last year. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. As a group, equities analysts forecast that Boston Scientific Corporation will post 3.38 EPS for the current year.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.